Hansberger Growth Investors LP grew its position in shares of GRIFOLS S A/S (NASDAQ:GRFS) by 5.2% during the first quarter, HoldingsChannel reports. The firm owned 109,327 shares of the biotechnology company’s stock after acquiring an additional 5,402 shares during the quarter. GRIFOLS S A/S makes up approximately 2.2% of Hansberger Growth Investors LP’s portfolio, making the stock its 17th biggest holding. Hansberger Growth Investors LP’s holdings in GRIFOLS S A/S were worth $2,199,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in GRFS. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of GRIFOLS S A/S by 9.1% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,296 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 526 shares in the last quarter. Advisors Asset Management Inc. raised its stake in shares of GRIFOLS S A/S by 58.0% in the fourth quarter. Advisors Asset Management Inc. now owns 3,629 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 1,332 shares in the last quarter. Advisor Group Inc. raised its stake in shares of GRIFOLS S A/S by 5.6% in the first quarter. Advisor Group Inc. now owns 26,465 shares of the biotechnology company’s stock valued at $532,000 after acquiring an additional 1,400 shares in the last quarter. Lenox Wealth Management Inc. raised its stake in shares of GRIFOLS S A/S by 0.7% in the first quarter. Lenox Wealth Management Inc. now owns 236,947 shares of the biotechnology company’s stock valued at $4,765,000 after acquiring an additional 1,652 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in shares of GRIFOLS S A/S by 2.3% in the first quarter. Bank of Montreal Can now owns 89,850 shares of the biotechnology company’s stock valued at $1,807,000 after acquiring an additional 2,017 shares in the last quarter. Institutional investors own 19.02% of the company’s stock.
GRFS has been the topic of several analyst reports. Zacks Investment Research cut GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, March 5th. BidaskClub cut GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 16th. Three equities research analysts have rated the stock with a sell rating and three have issued a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $19.00.
Shares of NASDAQ GRFS traded down $0.24 during mid-day trading on Friday, hitting $19.32. The company had a trading volume of 31,977 shares, compared to its average volume of 1,047,606. The stock has a market cap of $13.26 billion, a P/E ratio of 16.56, a PEG ratio of 1.15 and a beta of 1.04. The company has a current ratio of 2.87, a quick ratio of 1.13 and a debt-to-equity ratio of 1.41. GRIFOLS S A/S has a 1-year low of $17.42 and a 1-year high of $23.92.
GRIFOLS S A/S (NASDAQ:GRFS) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.25. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. GRIFOLS S A/S had a return on equity of 15.49% and a net margin of 12.35%. On average, equities analysts forecast that GRIFOLS S A/S will post 1.27 EPS for the current fiscal year.
The firm also recently announced a Semi-Annual dividend, which will be paid on Tuesday, June 18th. Investors of record on Monday, June 10th will be issued a $0.14 dividend. The ex-dividend date of this dividend is Friday, June 7th. GRIFOLS S A/S’s dividend payout ratio (DPR) is presently 1.71%.
ILLEGAL ACTIVITY WARNING: This story was first reported by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://theenterpriseleader.com/2019/06/14/hansberger-growth-investors-lp-grows-holdings-in-grifols-s-a-s-nasdaqgrfs.html.
GRIFOLS S A/S Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
See Also: Outstanding Shares
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.